ArticleKidney international2011
Candidate biomarkers for erythropoietin response in end-stage renal disease.
Article in Kidney international, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Personalized Therapeutic Advances in Erythropoietin Signaling: From Anemia Management to Extensive Clinical Applications.Pharmaceutics · 2025Review
- Skeletal muscle mass is associated with erythropoietin response in hemodialysis patients.BMC nephrology · 2021Article
- An Exploratory Study of Daprodustat in Erythropoietin-Hyporesponsive Subjects.Kidney international reports · 2018Article
- Factors precipitating erythropoiesis-stimulating agent responsiveness in a European haemodialysis cohort: case-crossover study.Pharmacoepidemiology and drug safety · 2015Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) is important clinically and economically. Escalation of dose may produce harm. Post hoc analyses of clinical trials showed that responsiveness could be predicted by hemoglobin response to a fixed dose escalation. This maneuver requires weeks to months. The study by Merchant et al. offers promise that peptidomic analyses of patient sera and mass spectrometry can identify biomarkers of both responsiveness and resistance to ESAs.
Indexed as
Identifiers
21321557What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.